Does the media favor BLCO or ZBH?

In the previous week, Zimmer Biomet had 11 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Zimmer Biomet and 6 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.05 beat Bausch + Lomb's score of 0.62 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BLCO or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% Solventum 17.33% 23.51% 7.63%

Does the media prefer BLCO or SOLV?

In the previous week, Bausch + Lomb and Bausch + Lomb both had 6 articles in the media. Bausch + Lomb's average media sentiment score of 0.62 beat Solventum's score of 0.38 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, BLCO or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.10B 1.04 -$360M -$0.62 N/A Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A

Does the media favor BLCO or SNN?

In the previous week, Bausch + Lomb had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Bausch + Lomb and 1 mentions for Smith & Nephew SNATS. Bausch + Lomb's average media sentiment score of 0.62 beat Smith & Nephew SNATS's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PEN or BLCO more profitable?

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media favor PEN or BLCO?

In the previous week, Bausch + Lomb had 4 more articles in the media than Penumbra. MarketBeat recorded 6 mentions for Bausch + Lomb and 2 mentions for Penumbra. Penumbra's average media sentiment score of 1.19 beat Bausch + Lomb's score of 0.62 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GKOS or BLCO?

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 12.84 -$187.69M -$3.28 N/A Bausch + Lomb $5.10B 1.04 -$360M -$0.62 N/A

Is GKOS or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media prefer GKOS or BLCO?

In the previous week, Bausch + Lomb had 3 more articles in the media than Glaukos. MarketBeat recorded 6 mentions for Bausch + Lomb and 3 mentions for Glaukos. Bausch + Lomb's average media sentiment score of 0.62 beat Glaukos' score of -0.27 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bausch + Lomb (BLCO) Competitors

$14.90 -0.08 (-0.53%)

As of 02:04 PM Eastern

Compare

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Bausch + Lomb compare to Zimmer Biomet?

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -4.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 11 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Zimmer Biomet and 6 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.05 beat Bausch + Lomb's score of 0.62 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A
Zimmer Biomet	$8.23B	1.99	$705.20M	$3.85	22.02

Bausch + Lomb presently has a consensus price target of $17.92, suggesting a potential upside of 20.08%. Zimmer Biomet has a consensus price target of $102.70, suggesting a potential upside of 21.15%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Bausch + Lomb has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Summary

Zimmer Biomet beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

In the previous week, Bausch + Lomb and Bausch + Lomb both had 6 articles in the media. Bausch + Lomb's average media sentiment score of 0.62 beat Solventum's score of 0.38 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.1% of Bausch + Lomb shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Bausch + Lomb currently has a consensus price target of $17.92, suggesting a potential upside of 20.08%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 8.37%. Given Bausch + Lomb's higher probable upside, research analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A
Solventum	$8.33B	1.62	$1.56B	$8.16	9.53

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Solventum	17.33%	23.51%	7.63%

Summary

Solventum beats Bausch + Lomb on 11 of the 15 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Bausch + Lomb (NYSE:BLCO) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

In the previous week, Bausch + Lomb had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Bausch + Lomb and 1 mentions for Smith & Nephew SNATS. Bausch + Lomb's average media sentiment score of 0.62 beat Smith & Nephew SNATS's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch + Lomb has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bausch + Lomb presently has a consensus target price of $17.92, suggesting a potential upside of 20.08%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 3.53%. Given Bausch + Lomb's higher probable upside, equities research analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Smith & Nephew SNATS	N/A	N/A	N/A

Summary

Bausch + Lomb beats Smith & Nephew SNATS on 8 of the 15 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Penumbra (NYSE:PEN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Bausch + Lomb had 4 more articles in the media than Penumbra. MarketBeat recorded 6 mentions for Bausch + Lomb and 2 mentions for Penumbra. Penumbra's average media sentiment score of 1.19 beat Bausch + Lomb's score of 0.62 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Penumbra has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.94	$177.69M	$4.34	73.48
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A

Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Bausch + Lomb	-4.21%	3.60%	1.69%

Penumbra currently has a consensus target price of $361.33, suggesting a potential upside of 13.30%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 20.08%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Penumbra beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Glaukos (NYSE:GKOS) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Glaukos has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Glaukos presently has a consensus price target of $146.17, suggesting a potential upside of 31.72%. Bausch + Lomb has a consensus price target of $17.92, suggesting a potential upside of 20.08%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Bausch + Lomb had 3 more articles in the media than Glaukos. MarketBeat recorded 6 mentions for Bausch + Lomb and 3 mentions for Glaukos. Bausch + Lomb's average media sentiment score of 0.62 beat Glaukos' score of -0.27 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	12.84	-$187.69M	-$3.28	N/A
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A

Summary

Glaukos and Bausch + Lomb tied by winning 8 of the 16 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.32B	$8.52B	$6.26B	$23.11B
Dividend Yield	N/A	1.77%	2.69%	4.09%
P/E Ratio	-24.06	22.12	22.37	31.03
Price / Sales	1.04	25.35	547.57	14.71
Price / Cash	9.22	90.05	42.31	24.78
Price / Book	0.81	5.00	9.79	4.68
Net Income	-$360M	$178.24M	$3.56B	$1.07B
7 Day Performance	-5.20%	-1.74%	-1.27%	-0.50%
1 Month Performance	-8.53%	2.98%	3.58%	0.39%
1 Year Performance	29.68%	1.70%	27.13%	25.64%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	4.7375 of 5 stars	$14.90 -0.5%	$17.92 +20.2%	+30.7%	$5.31B	$5.10B	N/A	13,000	Analyst Forecast
ZBH Zimmer Biomet	4.5999 of 5 stars	$82.46 -0.4%	$102.70 +24.5%	-8.1%	$15.93B	$8.23B	21.42	17,000	News Coverage Positive News Insider Trade
SOLV Solventum	3.1424 of 5 stars	$75.13 -1.1%	$84.25 +12.1%	+4.5%	$12.98B	$8.33B	9.21	20,000	High Trading Volume
SNN Smith & Nephew SNATS	1.8213 of 5 stars	$29.72 -0.2%	$30.93 +4.1%	+0.8%	$12.68B	$6.16B	N/A	16,988
PEN Penumbra	2.1736 of 5 stars	$318.46 -0.2%	$361.33 +13.5%	+24.2%	$12.52B	$1.40B	73.38	4,700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Is BLCO or ZBH more profitable?

Does the media favor BLCO or ZBH?

Do institutionals and insiders hold more shares of BLCO or ZBH?

Which has stronger earnings & valuation, BLCO or ZBH?

Do analysts rate BLCO or ZBH?

Which has more volatility and risk, BLCO or ZBH?

Summary

How does Bausch + Lomb compare to Solventum?

Does the media prefer BLCO or SOLV?

Do insiders & institutionals hold more shares of BLCO or SOLV?

Which has more volatility and risk, BLCO or SOLV?

Do analysts prefer BLCO or SOLV?

Which has preferable valuation & earnings, BLCO or SOLV?

Is BLCO or SOLV more profitable?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Does the media favor BLCO or SNN?

Which has more volatility & risk, BLCO or SNN?

Do insiders and institutionals have more ownership in BLCO or SNN?

Do analysts prefer BLCO or SNN?

Which has higher valuation & earnings, BLCO or SNN?

Is BLCO or SNN more profitable?

Summary

How does Bausch + Lomb compare to Penumbra?

Does the media favor PEN or BLCO?

Do insiders & institutionals have more ownership in PEN or BLCO?

Which has higher earnings & valuation, PEN or BLCO?

Which has more risk & volatility, PEN or BLCO?

Is PEN or BLCO more profitable?

Do analysts rate PEN or BLCO?

Summary

How does Bausch + Lomb compare to Glaukos?

Do insiders and institutionals hold more shares of GKOS or BLCO?

Which has more volatility and risk, GKOS or BLCO?

Do analysts recommend GKOS or BLCO?

Is GKOS or BLCO more profitable?

Does the media prefer GKOS or BLCO?

Which has higher valuation and earnings, GKOS or BLCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools